The use of metallic stents to bypass ureteral strictures secondary to metastatic prostate cancer: experience with 8 patients.
OBJECTIVE
We evaluated the middle term patency, incidence of infection and ability to preserve renal function using metallic stents to bypass ureteral obstruction secondary to metastatic prostate adenocarcinoma.


METHODS
We studied 8 patients with ureteral obstruction secondary to metastatic prostate adenocarcinoma at the pelvic ureter with up to 48 months of followup. Metallic Wallstents* 8 mm. in diameter and 64 mm. long were placed across the stricture after preliminary dilation with a high pressure balloon. Double-J catheters were left in all patients for at least 1 month or until mucosal edema had subsided. All stents were placed via an antegrade approach.


RESULTS
Average duration of stent patency was 19 months. All 6 patients at risk at 12 months had patent stents compared to 3 of 5 at 24 months, 2 of 2 at 36 months, and 1 of 1 at 48 months. Stent occlusion occurred in 2 patients at 8 and 12 months, respectively, and additional stents were placed telescopically to achieve recanalization. Renal function was preserved in all patients. Two patients died of disease at 1 month and 1 at 26 months after stent placement.


CONCLUSIONS
The use of metallic stents to bypass malignant ureteral obstruction is a safe and effective method.
López-Martínez
R A
RA
Department of Surgery, University of Medicine and Dentistry of New Jersy, New Jersey Medical School, Newark, USA.
Singireddy
S
S
Lang
E K
EK
D000230:Adenocarcinoma / Q000556:secondary*; D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D015607:Stents / Q000009:adverse effects; D014516:Ureteral Neoplasms / Q000150:complications* / Q000556:secondary*; D014517:Ureteral Obstruction / Q000209:etiology / Q000601:surgery*